Renovos Biologics has appointed Simon Sinclair as non-executive director

 In Company News

Simon Sinclair

Previously in clinical trials at Merck & Co. Inc. and in medical affairs at DePuy Synthes and Johnson & Johnson, Simon is now working in safety and vigilance at RB. This wealth of experience provides Simon with the knowledge within the orthopedic and tissue regeneration fields that Renovos is within, allowing Simon to guide Renovos with its product development, safety testing, clinical trials, and commercialisation.

When asked why he decided to join Renovos – a regenerative medicine start up – Simon responded with “Having contributed to the world of orthopaedic innovation in previous roles, Renovos stood out to me as an exceptional example. What really motivated me to join Renovos was the prospect of realising that innovative potential and bringing safer, better and more cost-effective surgical solutions to patients worldwide.”

It is exciting for Renovos to welcome someone with such experience onto the team and we are looking forward to not only working with Simon but also to the advances we can make with his support.

Recent Posts
Nanoclay platform technology injectable